Avoid common mistakes on your manuscript.
Dear Reader
As we approach the end of 2015, and mark the completion of the second volume of Drug Safety - Case Reports, the editors and production staff at Adis wish to reflect on a successful year’s achievements and pay thanks to all those who have contributed their time and effort to guarantee the exceptional quality of our content.
We are delighted to have seen the conclusion of formalities surrounding the joint venture between Springer Science + Business Media and Nature Publishing Group, Palgrave Macmillan, Macmillan Education in early May. Substantial ground has already been made in the integration of business within the resulting Springer Nature company and we at Adis look eagerly toward the future, as the benefits of the collective expertise and capabilities of this company carry us forward.
The majority of our journals saw a rise in ISI impact factor against the previous year. Most notably, BioDrugs increased by 41 % to 2.989; the European Journal of Drug Metabolism and Pharmacokinetics increased 19 % to 1.563; CNS Drugs increased by 17 % to 5.113; Targeted Oncology increased 16 % to 4.000; Pediatric Drugs increased 15 % to 1.975; Drugs & Aging increased 13 % to 2.838; and Molecular Diagnosis & Therapy increased a further 12 % to 2.891, having already jumped 53 % in the preceding year. We hope to build upon these gains, once more, in 2016.
The Adis Book programme has grown substantially and 20 new titles will have been published over the course of the year. Over 50 further titles are currently in development with leading academics, internationally, and we continue to add more to the list. Our thanks, again, to all who have submitted these valuable proposals to date.
We offer our sincere thanks to all authors who have contributed articles to Drug Safety - Case Reports since the journal’s launch in 2014. Their skill and dedication are critical to the continued publication of the journal. The world-class quality of published articles is, similarly, testament to the significant efforts of the peer reviewers, whose commitment ensures that our content is held to the highest possible standard. In addition to the members of our Honorary Editorial Board, we would like to thank the following individuals who acted as reviewers for articles published in Drug Safety - Case Reports since the journal began receiving submissions:
Frank Andersohn, Germany
Gary Asher, USA
Umit Avsar, Turkey
Jane P.F. Bai, USA
Donald L. Batisky, USA
Liberato Berrino, Italy
Corrado Blandizzi, Italy
Cheng Leng Chan, Singapore
Pieter-Jan Cortoos, Belgium
Paul de Boissieu, France
Thomas De Rijdt, Belgium
Kyle Eckhardt, Canada
Moses S. Elisaf, Greece
Jonathon Fanaroff, USA
John Fanikos, USA
Jacques Genest, Canada
Sophie Gosselin, Canada
Tuncay Gunduz, Turkey
Sebastian Harder, Germany
Iain P. Hargreaves, UK
Yi Ji, China
Christian Junghanss, Germany
Lisa Kalisch Ellett, Australia
Michel Lanteri-Minet, France
Setu Mathur, India
Bruno B. Megarbane, France
David Mendelowitz, USA
Martin Michel, Germany
Olivier Mimoz, France
James J. Nawarskas, USA
Brian C. Nelson, USA
Beth Parker, USA
Kaksha Patel, India
Verica Pavlic, Bosnia and Herzegovina
Emanuel Raschi, Italy
Cornelia Reichert, Switzerland
Gail Rowan, Australia
Stefania Scotto, Italy
Michael J. Shattock, UK
Satwika Sinha, India
Souad Skalli, Morocco
Claudia Spies, Germany
Nikol Sullo, UK
Melanie R. Symoniak, USA
Anne B. Taegtmeyer, Switzerland
Paz Toren, Israel
Albert Trinh-Duc, France
Marco Tuccori, Canada
Vedat Turhan, Turkey
Laszlo Vecsei, Hungary
Prabha Viswanathan, USA
Felix-Martin Werner, Germany
Elizabeth M. Williamson, UK
Erik B. Wilms, The Netherlands
Sameer A. Zope, India
We hope that you have found the articles published in Drug Safety - Case Reports to be both interesting and informative. The editors have appreciated the high quality of content contributed to the journal to date and look forward to keeping you up to date with drug safety-related case reports and case series in the year to come.
With best wishes from the staff of Drug Safety - Case Reports and all at Adis Publications.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Acknowledgement to Referees. Drug Saf - Case Rep 2, 18 (2015). https://doi.org/10.1007/s40800-015-0022-4
Published:
DOI: https://doi.org/10.1007/s40800-015-0022-4